Rebif (human IFN-β-1a) / EMD Serono  >>  Phase 4
Welcome,         Profile    Billing    Logout  

10 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rebif (human IFN-β-1a) / EMD Serono
2004-004903-39: A pilot multi-centre randomised controlled trial of sequential treatment with Mitoxantrone and Glatiramer Acetate vs. Interferon Beta-1a in early active relapsing remitting Multiple Sclerosis.

Ongoing
4
60
Europe
Mitoxantrone, Glatiramer Acetate, Interferon Beta 1a, , Injection*, Mitoxantrone, Copaxone, Rebif 44
The Walton Centre for Neurology and Neurosurgery
Early, active relapsing remitting Multiple Sclerosis (RRMS)
 
 
2006-000606-23: ?Post-authorization safety study to check the potential association between the safetyprofile of beta interferon 1a and the body mass index or pharmacodynamics during thetitration phase Estudio post-autorización de seguridad para determinar la posible asociación entre el perfil de seguridad de interferón beta-1a y el índice de masa corporal o los marcadores farmacodinámicos durante la fase de escalado de dosis.

Ongoing
4
100
Europe
Interferon-beta-1a, Solution for injection, Rebif 22 y 44 mcg
Merck, S.L., Merck, S.L.
Not applicalbe Esclerosis múltiple remitente recurrente, Not applicable Esclerosis múltiple remitente recurrente, Diseases [C] - Nervous System Diseases [C10]
 
 
2005-001008-37: Analysis of the antibody level against interferon beta before and after increase of dose in MS therapy

Ongoing
4
100
Europe
Rebif®, Not applicable, Rebif®, Rebif®
Sahlgrenska University Hospital
Multiple sclerosis
 
 
2007-004937-41: Etude du lien entre les marqueurs biologiques, la fatigue et les troubles cognitifs au cours de la sclérose en plaques de diagnostic récent et traitée par Interféron Bêta 1a SC (Rebif 44)

Ongoing
4
40
Europe
REBIF, REBIF, REBIF
Centre Hospitalier de Nancy
SLEROSE EN PLAQUE
 
 
2011-003570-89: The effect of interferon beta-1a treatment on adaptability of the brain in patients with MS Het effect van interferon beta-1a behandeling op het aanpassingsvermogen van de hersenen bij patienten met MS

Ongoing
4
100
Europe
Rebif, Rebif
VU University Medical Center, Merck Serono
Multiple sclerosis Multiple sclerose
 
 
2013-004626-28: Aivojen mikroglia-solujen aktivaation yhteys MS-tautiin

Ongoing
4
60
Europe
beetainterferoni -1a, Fingolimodi, REBIF, Gilenya, Avonex, Betaferon, Copaxone, Tysabri, Lemtrada, REBIF, Gilenya, Avonex, Betaferon, Copaxone, Tysabri, Lemtrada
Turku University Hospital, Novartis Pharma
Multiple sclerosis MS-tauti
 
 
2012-005450-30: Investigation of neutralising antibodies against interferon-beta in patients with multiple sclerosis, in order to find markers to predict the development of these antibodies and minimize the risk of ineffective therapy Erforschung der Bildung neutralisierender Antikörper gegen Interferon-beta bei Patienten mit Multipler Sklerose. Ziel ist es, Faktoren zu finden, mit denen man die Ausbildung solcher Antikörper vorhersagen und damit das Risiko einer unwirksamen Therapie vermindern kann

Ongoing
4
50
Europe
Avonex, Rebif, Betaferon, Extavia, Avonex, Rebif, Betaferon, Extavia
Medizinische Universität Innsbruck, ABIRISK
Development of neutralising antibodies against Interferon-beta in the treatment of multiple sclerosis Entwicklung neutralisierender Antikörper gegen Interferon-beta in der Therapie der Multiplen Sklerose
 
 
2017-002634-24: MultipleMS – a study with the aim to accelerate personalised medicine in multiple sclerosis. MultipleMS - en studie med syftet att utveckla precisionsmedicin för multipel skleros.

Ongoing
4
150
Europe
Infusion, Capsule, Tablet, Injection, Mabthera, Tysabri, Tecfidera, Gilenya, Copaxone, Betaferon, Extavia, Avonex, Rebif, Plegridy, Lemtrada, Aubagio
Karolinska Institutet, Department of Clinical Neuroscience, Karolinska Institutet
Newly diagnosed patients with Clinically Isolated Syndrome (CIS) and multiple sclerosis (MS) -both relapsing remitting and primary progressive), Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system (CNS), characterized by repeated episodes of inflammation in the CNS leading to various neurological symptoms., Diseases [C] - Nervous System Diseases [C10]
 
 
2016-004819-12: Discontinuation of first-line disease modifying treatment (DMT) in long-term full responders MS patients Sclerosi Multipla: effetti della sospensione del trattamento protratto con farmaci immunomodulanti di prima linea in pazienti "full responders"

Ongoing
4
300
Europe
Interferone Beta-1B, Inteferone Beta-1A, Glatiramer acetato, Interferon Beta-1a, [032166011], [033283045], [035418060], [034091165], Powder and solvent for solution for injection, Solution for injection, BETAFERON - 15 FLACONCINI 0.25 MG + 15 FLACONCINI 2 ML, AVONEX - 30 MCG (6 MILIONI UI) POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 4 FLACONI CON DISPOSITIVO BIOSET + 4 SIRINGHE PRERIEMPITE USO INTRAMUSCOLARE, COPAXONE - "40 MG/ML SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA" 12 SIRINGHE PRERIEMPITE DA 1 ML CON AGO, REBIF - 44 MCG(12 MILIONI UI) -SOLUZ INIETTABILE- USO SOTTOCUTANEO-PENNA PRERIEMPITA 0.5 ML (24 MILIONI UI/ML)12 PENNE PRERIEMPITE
OSPEDALE SAN RAFFAELE, AIFA - Italian Medicines Agency
Relapsing-Remitting multiple sclerosis (RR-MS), Sclerosi Multipla Recidivante Remittente, Relapsing-Remitting multiple sclerosis (RR-MS), Sclerosi Multipla Recidivante Remittente, Diseases [C] - Nervous System Diseases [C10]
 
 
DELIVER-MS, NCT03535298: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Active, not recruiting
4
800
Europe, US
Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod)
The Cleveland Clinic, University of Nottingham
Multiple Sclerosis, Relapsing-Remitting
07/27
09/30

Download Options